Impact of chronic kidney disease on platelet function profiles in diabetes mellitus patients with coronary artery disease taking dual antiplatelet therapy.
about
Current status of high on-treatment platelet reactivity in patients with coronary or peripheral arterial disease: Mechanisms, evaluation and clinical implicationsThe Impact of Renal Dysfunction on the Long Term Clinical Outcomes of Diabetic Patients Undergoing Percutaneous Coronary Intervention in the Drug-Eluting Stent EraEffects of clopidogrel on mortality, cardiovascular and bleeding outcomes in patients with chronic kidney disease - data from Taiwan acute coronary syndrome full spectrum registry.Frequency of heparin/platelet factor 4-dependent platelet antibodies in patients undergoing angioplasty and stenting for cardiovascular disease and their role for on-clopidogrel platelet reactivity.Low-dose aspirin for prevention of cardiovascular disease in patients with chronic kidney disease.Is there attenuation of benefit of invasive therapy in patients with chronic kidney disease? Results from randomized trials and registry data.Peripheral artery disease and chronic kidney disease: clinical synergy to improve outcomes.Interleukin-6 and asymmetric dimethylarginine are associated with platelet activation after percutaneous angioplasty with stent implantation.Chronic kidney disease and coronary artery vulnerable plaques.Increased atherothrombotic burden in patients with diabetes mellitus and acute coronary syndrome: a review of antiplatelet therapyDifferences in Whole Blood Platelet Aggregation at Baseline and in Response to Aspirin and Aspirin Plus Clopidogrel in Patients With Versus Without Chronic Kidney Disease.Myocardial Stunning with Hemodialysis: Clinical Challenges of the Cardiorenal Patient.The impact of chronic kidney disease on lipid management and goal attainment in patients with atherosclerosis diseases in Taiwan.Coronary artery disease in patients with chronic kidney disease: a clinical update.Pharmacokinetic and Pharmacodynamic Responses to Clopidogrel: Evidences and Perspectives.Antithrombotic therapy in patients with diabetes mellitus and coronary artery disease.The role of antiplatelets in hypertension and diabetes mellitus.Genetic and non-genetic factors affecting the response to clopidogrel therapy.Acute coronary syndromes: identifying the appropriate patient for prasugrel.Diabetes mellitus and acute coronary syndrome: lessons from randomized clinical trials.Stent thrombosis in patients with chronic kidney disease.Antiplatelet therapy in the management of cardiovascular disease in patients with CKD: what is the evidence?Metabolic differences of current thienopyridine antiplatelet agents.Platelet function profiles in patients with diabetes mellitus.Management of cardiovascular disease in patients with kidney disease.Efficacy of clopidogrel treatment and platelet responsiveness in peripheral arterial procedures.Prognostic Implications of Chronic Kidney Disease on Patients Presenting with ST-Segment Elevation Myocardial Infarction with versus without Stent Thrombosis.Oral P2Y12 Receptor Inhibitors in Hemodialysis Patients Undergoing Percutaneous Coronary Interventions: Current Knowledge and Future Directions.Dual Antiplatelet Therapy and Clinical Outcomes after Coronary Drug-Eluting Stent Implantation in Patients on Hemodialysis.Oral antiplatelet drugs in patients with chronic kidney disease (CKD): a review.Diabetes, diabetes severity, and coronary heart disease risk equivalence: REasons for Geographic and Racial Differences in Stroke (REGARDS)The Personalization of Clopidogrel Antiplatelet Therapy: The Role of Integrative Pharmacogenetics and Pharmacometabolomics.Impact of chronic kidney disease on long-term ischemic and bleeding outcomes in medically managed patients with acute coronary syndromes: Insights from the TRILOGY ACS Trial.Chronic kidney disease is associated with increased platelet activation and poor response to antiplatelet therapy.Chronic kidney disease and the risk of stent thrombosis after percutaneous coronary intervention with drug-eluting stents.Pharmacogenomic Impact of CYP2C19 Variation on Clopidogrel Therapy in Precision Cardiovascular Medicine.The Association between Glomerular Filtration Rate Estimated on Admission and Acute Stroke Outcome: The Shiga Stroke Registry.Platelet reactivity in stable cardiovascular patients with chronic kidney disease.Pharmacodynamics and pharmacokinetics of ticagrelor vs. clopidogrel in patients with acute coronary syndromes and chronic kidney disease.Antiplatelet Therapy in ACS Patients: Comparing Appropriate P2Y12 Inhibition by Clopidogrel to the Use of New P2Y12 Inhibitors.
P2860
Q26771106-BE5DB525-4DD8-4523-AEB2-CE80DCB46269Q28552019-AD703EB9-5023-4FF2-AA2D-DEEA8C6722F8Q30665648-5BC21426-6124-4E8D-86DA-2C2FEBF1881FQ33399119-A58D8694-800B-42A8-87D5-B6F700674C73Q34005232-9CCDD479-5F88-47A9-B026-B0BEDB6FB048Q34283808-26EBECFA-D4D2-44C4-9ED4-A404F9208505Q34625055-B1EE2C07-B5D0-4C36-BA7A-2082C9282860Q35216871-461AFA4F-8001-47CA-86B2-4A2B10BD2546Q35664598-9DEC5C86-ED95-43F4-9002-1BC465C3DDBBQ35755253-03B55BBA-0901-4774-AEF7-8BEE7B8045D9Q35883494-BBF010B3-FFA2-4FC1-95D4-4654697F066AQ36036002-4FBD6D67-7C06-429D-988C-F7DC52399E27Q37605410-4029C2B5-01FE-4986-8436-A128640EAF76Q37614917-D40E1F1D-AF78-4FFD-9043-8FCD212716BBQ37724614-0EE02026-1776-4755-9FB2-A888292A6794Q37797795-D2511D4D-B5AF-417D-90B4-8A1EFF342D92Q37861894-E0D48AD9-D752-467B-83A6-733C80C82281Q37991382-6978420E-D598-43FF-B49E-C16F69C6D36DQ37995859-86825FF7-0D2C-48B6-941E-65FCAD82688EQ38005018-FC91C133-C626-4FB7-9B32-FB4A8E230DB3Q38014979-5B7CAFE2-3D06-4064-9C53-EED3F2A7C65CQ38048245-1452EEB2-A49F-459B-B8A1-FDEB3F8D31EBQ38071707-3F798E5D-2695-4A79-9F4D-78D1F9CBBB10Q38081078-DBEA92FE-4596-46AB-B388-093C0A5B6B4FQ38082646-F9FB8FF1-BA86-480C-941D-4026694B2E82Q38243854-5E7A381C-7846-4EC1-BE25-9DC6533346ECQ38726862-9543AEB9-4C5B-47A5-83FE-4D94C36C7CDAQ38802950-F1094C9F-854A-4056-BF4B-A873E539C088Q38973363-69076864-667A-41DC-9ADF-185E8A269F43Q39147420-EF0789F8-35EA-4611-880F-A4F4AAF7C327Q39205827-494A9C2E-50D0-4D95-BC77-71D670340865Q39249688-E8C0D5B8-B52A-46C7-B210-0EEA19EFC02FQ41528609-992A4BE5-6244-407F-9AD3-3F8878F0D6C2Q43498064-87BBFD02-8CEF-4B80-A06E-5E7CBB53437BQ46944476-029BED7A-3040-4F68-9B8C-AA353B9895AAQ47554139-67031523-7D1C-4FAB-8BCE-AC21A57E7CB7Q47558400-36AD0400-6362-4D04-8D0E-DDCBE0CB25D5Q48329778-EE056B35-6027-4CBD-87A4-6D521D32052FQ48332605-AE3C6851-51DF-4322-8A58-A0F0B94BAEF7Q48507719-E1C3F3FE-6763-4E32-A714-D6D16EE33005
P2860
Impact of chronic kidney disease on platelet function profiles in diabetes mellitus patients with coronary artery disease taking dual antiplatelet therapy.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Impact of chronic kidney disea ...... ing dual antiplatelet therapy.
@en
Impact of chronic kidney disea ...... ing dual antiplatelet therapy.
@nl
type
label
Impact of chronic kidney disea ...... ing dual antiplatelet therapy.
@en
Impact of chronic kidney disea ...... ing dual antiplatelet therapy.
@nl
prefLabel
Impact of chronic kidney disea ...... ing dual antiplatelet therapy.
@en
Impact of chronic kidney disea ...... ing dual antiplatelet therapy.
@nl
P2093
P50
P1476
Impact of chronic kidney disea ...... ing dual antiplatelet therapy.
@en
P2093
Carlos Macaya
David Vivas
Dominick J Angiolillo
Esther Bernardo
Fernando Alfonso
Manel Sabaté
Masafumi Ueno
Pilar Jimenez-Quevedo
Theodore A Bass
P304
P356
10.1016/J.JACC.2009.10.043
P407
P577
2010-03-01T00:00:00Z